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The rationale behind endocrine therapy for breast cancer is
the knowledge that certain tumours require oestrogen for
their continued growth. Sources of oestrogen differ according
to menopausal status; ovarian production predominates in
premenopausal women whereas synthesis in peripheral tissues
such as fat, muscle and the tumour itself is more important in
post-menopausal patients (Miller, 1990). The use of drugs
specifically designed to block oestrogen biosynthesis irrespec-
tive of site of production is therefore an attractive strategy.
Oestrogens lie at the end of a multistep pathway. Blockade
can be achieved by inhibiting any of the individual
transformations but more specific suppression is achieved
by inhibiting the final step, which is unique to oestrogen
biosynthesis. This reaction converts androgens into oestro-
gens by creating an aromatic ring in the steroid molecule
(hence the trivial name for the enzyme of 'aromatase').
Consequently, enormous efforts have been expended in the
development of aromatase inhibitors by synthesising either
substrate analogues or drugs that interfere with the enzyme's
prosthetic cytochrome p450 group.
It has been known for some time that drug-induced
inhibition of the aromatase enzyme may produce therapeutic
benefits in patients with breast cancer. Agents such as
aminoglutethimide were used without initially realising that
they had anti-aromatase properties. Nevertheless, the major
benefits of aminoglutethimide (which include a 33% objective
response rate in unselected post-menopausal patients with
advanced breast cancer) are probably achieved through
inhibition of the aromatase system (Miller, 1989). However,
aminoglutethimide is not a potent aromatase inhibitor; it also
lacks specificity and side-effects may be produced that are
unrelated to oestrogen deprivation. Considerable resources
have been invested in the development of second- and third-
generation drugs (Combs et al., 1995). Results of studies on
these aromatase inhibitors are now being published, as is
reflected by the current issue of the Br. J. Cancer, which
contains two such articles (Yates et al., 1996 and Bonnefoi et
al., 1996). It is thus opportune to review the current status of
these drugs in terms of (i) anti-aromatase and endocrinolo-
gical effects, (ii) clinical tolerability and efficacy, (iii)
relationship with established endocrine treatments, (iv)
future applications and (v) theoretical and practical
perspectives.
This potential is reflected by in vivo effects on circulating
oestrogens. For example in this current issue Yates et al.
report that small doses of Arimidex suppress oestradiol levels
by about 80% and, in a number of subjects, values fell below
limits of detection. These effects were achieved without
significant influences on other classes of steroid hormones.
Similar results have been reported by others for letrozole
(Demers, 1994; Lipton et al., 1995), and vorozole (Johnston
et al., 1994; Goss et al., 1995). Of the new non-steroidal
aromatase inhibitors, fadrozole seems less effective in both
inhibiting aromatase and suppressing circulating oestrogens
(Demers, 1994). Doubts have also been expressed about its
specificity; changes in aldosterone secretion have been
reported (Demers et al., 1993), but at doses that produce
maximal suppression of oestrogen, effects on aldosterone may
not be of clinical significance (Dowsett et al., 1994).
Clinical tolerability and efficacy
These new aromatase inhibitors are administered orally (the
exception is formestane, which requires intramuscular
injection) and appear to be remarkably well tolerated, with
no greater incidence of side-effects than might be expected
from a placebo or from oestrogen suppression. However, it
should be noted that the duration of treatment in most
patients is still extremely limited.
Despite the drugs being initially used in heavily pretreated
patients with advanced disease, anti-tumour effects are
encouraging. Formestane has been associated with an
objective response rate of 33% and remissions have been
seen in patients previously treated with aminoglutethimide
(Coombes, 1989). This issue includes a report that fadrozole
produces a 17% objective response rate in recurrent breast
cancer after tamoxifen failure (Bonnefoi et al., 1996). Similar
observations in tamoxifen-resistant disease have been made
for vorozole, with Johnston et al. (1994) reporting a 33%
response rate and Goss et al. (1995) a 17% rate. Early data
on letrozole also indicate that beneficial tumour remissions
may be achieved in patients resistant to other endocrine and
chemotherapeutic manoeuvres (Smith et al., 1994). Given this
promise it is essential that direct comparative studies are
performed against established endocrine therapies. Clinical
trials of primary treatment are underway and their results are
Anti-aromatase and endocrinological effects
Among the drugs under current scrutiny are steroidal
analogues such as formestane and exemestane and non-
steroidals such as fadrozole, vorozole, letrozole and
Arimidex. All are substantially more potent than aminoglu-
tethimide as inhibitors of the aromatase enzyme (see Table I).
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Table I Relative in vitro potency of aromatase inhibitors as










eagerly awaited. Interestingly, a comparison of formestane
and tamoxifen as primary treatment found similar response
rates with both drugs (Perez-Carrion et al., 1994).
Relationship with established endocrine treatments
That responses have been achieved with the new aromatase
inhibitors following treatment failure with antioestrogens or
less powerful aromatase inhibitors suggests that they warrant
a place as second-line endocrine therapies. Whether they can
replace tamoxifen as a first-line therapy in all or some
patients depends upon the results of on-going trials. Even if
response rates and toxicities are similar to those of tamoxifen,
there may be a lesson to be learnt from the experience with
aminoglutethimide. Thus, response rates to first-line therapy
with tamoxifen and aminoglutethimide are similar but,
whereas aminoglutethimide is effective in about 30% of
patients when given as second-line therapy to tamoxifen, the
antioestrogen less frequently causes remission after amino-
glutethimide (Smith et al., 1981), which dictates a logical
sequence of tamoxifen followed by aminoglutethimide.
Whether this phenomenon will apply to other more specific
aromatase inhibitors is unknown. (One aspect of aminoglu-
tethimide's lack of specificity may be to enhance drug
metabolism; Lonning, 1990). Similarly, the disappointing
results obtained when aminoglutethimide is combined with
other endocrine procedures (Smith et al., 1982) should not
deter the use of combination therapies based around newer
aromatase inhibitors. The concept of using potent antioestro-
gens in tandem with equally potent aromatase inhibitors to
achieve total oestrogen blockade may yet prove irresistible
(but see below).
Future applications
The potent and specific characteristics of the new aromatase
inhibitors suggest that they may have a wider utility than
previous drugs. For example, it has always been puzzling as
to why aromatase inhibitors should be effective after failure
to antioestrogen if both types of drug have a common
mechanism of oestrogen deprivation but the commonly
expounded reasons for this are (i) antioestrogens such as
tamoxifen are partial oestrogen agonists and may compete
ineffectively for oestrogen receptors or (ii) under the selective
pressure of antioestrogen treatment tumours become increas-
ingly sensitive to oestrogen. In these circumstances aromatase
inhibitors that reduce oestrogen levels may produce anti-
tumour effects. If this is the case, more potent aromatase
inhibitors that suppress oestrogen levels beyond those
previously achievable, could increase cell kill and produce
higher response rates.
A second area for exploitation is as an adjuvant to surgery
in early stages of the disease. The acceptability of adjuvant
therapy depends critically upon lack of side-effects. This is
especially important for adjuvant endocrine therapy, which
probably needs to be given over an extended time period for
most beneficial effects. Because, in comparison with previous
aromatase inhibitors, second- and third-generation drugs
appear to lack toxicity, there is pressure for adjuvant use.
However, this may be premature until results are available on
long-term administration. The concern is that prolonged
suppression of oestradiol to unassayable levels may have
severe detrimental effects on bone and the vasculature.
More potent aromatase inhibitors may also be effective in
situations in which aromatase activity is high or induced. For
example aminoglutethimide is not effective in premenopausal
women (Harris et al., 1982), presumably because it cannot
inhibit the inherently high aromatase activity in the ovary or
the reflex feedback loops that result in compensatory
increases in enzyme and androgen substrate. More potent
and specific inhibitors may be able to be given in sufficient
doses to overcome these effects and suppress oestrogens to
post-menopausal levels.
Theoretical and practical perspectives
There are theoretical reasons as to why specific aromatase
inhibitors may not achieve complete oestrogenic blockade in
vivo. Thus, whereas the drugs inhibit peripheral aromatase
almost completely, levels ofcirculating oestrogens fall only by
40-85% (Masamura et al., 1994). Specific aromatase
inhibitors, even if totally effective, will not effect (1) the
synthesis of androgens such as A 5-androstenediol, which are
capable of oestrogenic effects (Hackenberg et al., 1993), nor
(2) the action of exogenous oestrogens such as dietary phyto-
oestrogens and industrial contaminants such as pesticides and
plasticisers (which may act as weak oestrogens). Although
controversial, it is possible that these alternative oestrogenic
sources may maintain hormone-dependent tumour growth. In
these circumstances, pure antioestrogens have greater
versatility in that they should block trophic effects
irrespective of the source of oestrogen. However, potent
specific aromatase inhibitors are powerful tools for research
and their use is likely to yield fundamental information about
aromatase activity and the diverse sources of oestrogens.
Finally there is the practical consideration as to which of
the new inhibitors will make the greatest clinical impact. At
present, this is impossible to answer. Several inhibitors have
similar profiles with regard to their potency, specificity,
clinical efficacy and tolerability. It may come down to cost
and marketing - a chastening thought given the vast
scientific/clinical effort invested in developing and assessing
the drugs.
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